Generic Rinvoq LQ Availability
Last updated on Apr 10, 2025.
See also: Generic Rinvoq
Rinvoq LQ is a brand name of upadacitinib, approved by the FDA in the following formulation(s):
RINVOQ LQ (upadacitinib - solution;oral)
-
Manufacturer: ABBVIE
Approval date: April 26, 2024
Strength(s): 1MG/ML [RLD]
Is there a generic version of Rinvoq LQ available?
No. There is currently no therapeutically equivalent version of Rinvoq LQ available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rinvoq LQ. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Patent 10,981,923
Issued: April 20, 2021
Inventor(s): Allian; Ayman et al.
Assignee(s): AbbVie Inc. (North Chicago, IL)The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Patent 11,186,584
Issued: November 30, 2021
Inventor(s): Allian Ayman & Jayanth Jayanthy & Mohamed Mohamed-Eslam F. & Mulhern Mathew & Nordstrom Fredrik Lars & Othman Ahmed A. & Rozema Michael J. & Bhagavatula Lakshmi & Marroum Patrick J. & Mayer Peter T. & Sheikh Ahmad Y. & Borchardt Thomas B. & Klünder Ben
Assignee(s): AbbVie Inc.The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Patent 11,661,425
Issued: May 30, 2023
Inventor(s): Allian; Ayman et al.
Assignee(s): AbbVie Inc. (North Chicago, IL)The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Patent 11,680,069
Issued: June 20, 2023
Inventor(s): Allian; Ayman et al.
Assignee(s): AbbVie Inc. (North Chicago, IL)The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Patent 11,718,627
Issued: August 8, 2023
Inventor(s): Allian; Ayman
Assignee(s): AbbVie Inc. (North Chicago, IL)The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]- pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Patent 11,773,105
Issued: October 3, 2023
Inventor(s): Allian; Ayman
Assignee(s): AbbVie Inc. (North Chicago, IL)The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Patent 12,110,298
Issued: October 8, 2024
Inventor(s): Mulhern; Mathew M. et al.
Assignee(s): AbbVie Inc. (North Chicago, IL)The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Tricyclic compounds
Patent 8,962,629
Issued: February 24, 2015
Inventor(s): Wishart Neil & Argiriadi Maria A. & Calderwood David J. & Ericsson Anna M. & Fiamengo Bryan A. & Frank Kristine E. & Friedman Michael M. & George Dawn M. & Goedken Eric R. & Josephsohn Nathan S. & Li Biqin C. & Stewart Kent D. & Wallace Grier A. & Wang Lu & Woller Kevin R.
Assignee(s): AbbVie Inc.The invention provides a compound of Formula (I)
Patent expiration dates:
- January 15, 2031✓✓
- January 15, 2031✓✓
- January 15, 2031
-
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Patent 9,951,080
Issued: April 24, 2018
Inventor(s): Allian Ayman
Assignee(s): AbbVie Inc.The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Patent expiration dates:
- October 17, 2036✓
- October 17, 2036
-
Tricyclic compounds
Patent RE47221
Issued: February 5, 2019
Inventor(s): Wishart Neil & Frank Kristine E. & Friedman Michael & George Dawn M. & Stewart Kent D. & Wallace Grier A.
Assignee(s): AbbVie Inc.The invention provides compounds of Formula (I) and Formula (II)
Patent expiration dates:
- August 16, 2033✓
- August 16, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 26, 2027 - NEW PRODUCT
- April 26, 2031 - TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TUMOR NECROSIS FACTOR (TNF) BLOCKERS, AND FOR THE TREATMENT OF PEDIATRIC PAT
More about Rinvoq LQ (upadacitinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: antirheumatics
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
